Why Adbry Costs $718.00 Per Claim
Adbry (Tralokinumab) is used to treat dermatology. According to CMS Medicare Part D spending data, the program spent $178.0M on this drug, covering 28,000 beneficiaries across 248,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Tralokinumab or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Adbry increased by +42.4% year-over-year, driven by increased utilization among Medicare beneficiaries.
Price Breakdown
Drug Details
Frequently Asked Questions
Adbry (Tralokinumab) costs an average of $718.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $6,357.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Adbry averages $718.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Adbry reflects in our Medicare Part D average of $718.00 per claim. Switching to generic Tralokinumab typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Adbry, but coverage varies by formulary tier. Insurers typically prefer generic Tralokinumab (Tier 1, lowest copay) over brand-name Adbry (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Tralokinumab is the single biggest cost reducer if your prescriber is open to it.
Brand-name Adbry costs more than generic Tralokinumab primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Adbry (Tralokinumab) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Tralokinumab.
Medicare Part D spent $178.0M on Adbry, covering 28,000 beneficiaries across 248,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Tralokinumab, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
For this entity, the underlying data on this page comes from CMS Medicare Part D Drug Spending data. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.